Critical issues in mucosal immunity for HIV-1 vaccine development

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

卷:122

Review

Haynes, Barton F.^1,2  Shattock, Robin J.³ 

[1] Duke Univ, Human Vaccine Inst, Sch Med, Dept Immunol, Durham, NC 27710 USA

[2] Duke Univ, Human Vaccine Inst, Sch Med, Dept Med, Durham, NC 27710 USA

[3] St Georges Univ, Dept Cellular & Mol Med, London, England

关键词: HIV-1;    vaccine;    mucosal;    gastrointestinal tract;    T cells;    antibody;    innate;    adaptive;    immunity;   

DOI  :  10.1016/j.jaci.2008.03.036

来源: Elsevier

【 摘 要 】

Development of a safe and effective vaccine for HIV-1 infection is a critical global priority. However, the nature of host-virus interactions that lead to early immunosuppression and CD4 depletion, HIV-1 diversity, and the inability of the immune system to eliminate the latently infected CD4 pool of cells has to date thwarted successful vaccine development. Moreover, both the initial antibody-inducing vaccine (protein envelope gp120) and cell-mediated vaccine (recombinant adenovirus containing HIV-1 genes) strategies have failed in efficacy trials, and the latter cell-mediated vaccine appeared to have caused enhanced HIV-1 acquisition. Thus basic and translational research to understand why current vaccines have failed and elucidation of new mechanisms of virus control at mucosal surfaces is essential for eventual successful development of a preventive HIV-1 vaccine.

【 授权许可】

Free